Published in Oncoimmunology on September 01, 2012
Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis. Nat Rev Cardiol (2015) 1.01
Experimental evidence of ω-3 polyunsaturated fatty acid modulation of inflammatory cytokines and bioactive lipid mediators: their potential role in inflammatory, neurodegenerative, and neoplastic diseases. Biomed Res Int (2013) 0.89
Monocytes and macrophages as nanomedicinal targets for improved diagnosis and treatment of disease. Expert Rev Mol Diagn (2013) 0.88
A role for versican in the development of leiomyosarcoma. J Biol Chem (2014) 0.83
Hypoxia promotes glioma-associated macrophage infiltration via periostin and subsequent M2 polarization by upregulating TGF-beta and M-CSFR. Oncotarget (2016) 0.81
Tumour cell derived effects on monocyte/macrophage polarization and function and modulatory potential of Viscum album lipophilic extract in vitro. BMC Complement Altern Med (2015) 0.77
Interplay of extracellular matrix and leukocytes in lung inflammation. Cell Immunol (2016) 0.75
Effects of IRF1 and IFN-β interaction on the M1 polarization of macrophages and its antitumor function. Int J Mol Med (2016) 0.75
Provisional matrix: A role for versican and hyaluronan. Matrix Biol (2016) 0.75
Versican deficiency significantly reduces lung inflammatory response induced by polyinosine-polycytidylic acid stimulation. J Biol Chem (2016) 0.75
The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol (2004) 19.38
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85
Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 14.55
Development of monocytes, macrophages, and dendritic cells. Science (2010) 12.86
Alternative activation of macrophages: mechanism and functions. Immunity (2010) 12.43
Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med (2001) 9.99
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol (2010) 9.59
Distinct role of macrophages in different tumor microenvironments. Cancer Res (2006) 9.29
CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell (2009) 8.54
Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol (2010) 6.85
Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell (2008) 6.78
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature (2009) 6.67
Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res (2007) 6.60
Macrophage polarization in tumour progression. Semin Cancer Biol (2008) 4.62
"Re-educating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med (2008) 4.38
Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev (2006) 4.02
Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol (2008) 3.02
p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res (2006) 2.76
Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol (2006) 2.67
High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res (2007) 2.63
Reversing lipopolysaccharide toxicity by ligating the macrophage Fc gamma receptors. J Immunol (2001) 2.49
Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J Leukoc Biol (2001) 2.26
The interaction of versican with its binding partners. Cell Res (2005) 2.22
Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J Immunol (2000) 2.17
Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol (1998) 2.11
The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res (2002) 1.99
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest (2011) 1.90
The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev (2006) 1.90
The roles of versican V1 and V2 isoforms in cell proliferation and apoptosis. Mol Biol Cell (2005) 1.85
Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell (2008) 1.80
IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J Immunol (2007) 1.67
Global profiling of reactive oxygen and nitrogen species in biological systems: high-throughput real-time analyses. J Biol Chem (2011) 1.63
Monocyte-like and mature macrophages produce CXCL13 (B cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis. Blood (2004) 1.61
Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages. Cancer Res (2009) 1.57
Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J Transl Med (2007) 1.51
Workflow comparison for label-free, quantitative secretome proteomics for cancer biomarker discovery: method evaluation, differential analysis, and verification in serum. J Proteome Res (2010) 1.42
Macrophages direct tumour histology and clinical outcome in a colon cancer model. J Pathol (2005) 1.40
Interactions among dendritic cells, macrophages, and epithelial cells in the gut: implications for immune tolerance. Curr Opin Immunol (2008) 1.40
Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep (2003) 1.37
Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clin Cancer Res (2002) 1.36
Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clin Cancer Res (1998) 1.33
The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer. J Transl Med (2010) 1.33
Macrophages: modulators of breast cancer progression. Novartis Found Symp (2004) 1.32
Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol (2001) 1.31
Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects. J Immunol (2006) 1.27
Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions. Cytokine (2008) 1.25
Role of versican, hyaluronan and CD44 in ovarian cancer metastasis. Int J Mol Sci (2011) 1.22
Prognostic relevance of tumour-associated macrophages and von Willebrand factor-positive microvessels in colorectal cancer. Virchows Arch (2004) 1.16
Versican in epithelial ovarian cancer: relation to hyaluronan, clinicopathologic factors and prognosis. Int J Cancer (2003) 1.14
Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: Association with progression and prognosis. Cancer Sci (2007) 1.14
From phagocyte diversity and activation to probiotics: back to Metchnikoff. Eur J Immunol (2008) 1.11
Prognostic significance of stromal versican expression in human endometrial cancer. Ann Oncol (2006) 0.99
Up-regulation of stromal versican expression in advanced stage serous ovarian cancer. Gynecol Oncol (2010) 0.96
Tumor infiltrating macrophages reduce development of peritoneal colorectal carcinoma metastases. Cancer Lett (2008) 0.95
The role of macrophages in tumor development. Cell Oncol (2005) 0.91
Clinical significance of syndecan-1 and versican expression in human epithelial ovarian cancer. Oncol Rep (2010) 0.91
Tumor-specific bacteriophages induce tumor destruction through activation of tumor-associated macrophages. J Immunol (2009) 0.90
Tumor-associated macrophages and dendritic cells as prototypic type II polarized myeloid populations. Tumori (2004) 0.90
Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase. Cancer Res (1995) 0.89
High stromal versican expression predicts unfavourable outcome in oral squamous cell carcinoma. J Clin Pathol (2006) 0.88
Quantification of the chemokines CCL17 and CCL22 in human colorectal adenocarcinomas. Mol Med Rep (2011) 0.81
Immunoglobulin A: Fc(alpha)RI interactions induce neutrophil migration through release of leukotriene B4. Gastroenterology (2009) 0.80
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Resolving the resolution of array CGH. Genomics (2007) 3.66
BAC to the future! or oligonucleotides: a perspective for micro array comparative genomic hybridization (array CGH). Nucleic Acids Res (2006) 3.32
Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology (2008) 3.18
Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res (2008) 3.06
Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect. Nat Genet (2005) 2.71
Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J Clin Invest (2003) 2.66
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol (2006) 2.33
N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst (2009) 2.22
PPIB mutations cause severe osteogenesis imperfecta. Am J Hum Genet (2009) 2.16
Human and mouse oligonucleotide-based array CGH. Nucleic Acids Res (2005) 2.03
Macrophages in skin injury and repair. Immunobiology (2011) 2.00
Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer. J Clin Oncol (2007) 1.97
Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol (2010) 1.90
Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res (2009) 1.80
GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin Cancer Res (2009) 1.78
On the beta-binomial model for analysis of spectral count data in label-free tandem mass spectrometry-based proteomics. Bioinformatics (2009) 1.74
Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer (2010) 1.69
Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res (2008) 1.69
Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut (2010) 1.68
The importance of human FcgammaRI in mediating protection to malaria. PLoS Pathog (2007) 1.61
Celecoxib treatment reduces peritoneal fibrosis and angiogenesis and prevents ultrafiltration failure in experimental peritoneal dialysis. Nephrol Dial Transplant (2009) 1.57
Proteomics analysis of rat brain postsynaptic density. Implications of the diverse protein functional groups for the integration of synaptic physiology. J Biol Chem (2003) 1.56
Higher fecal immunochemical test cutoff levels: lower positivity rates but still acceptable detection rates for early-stage colorectal cancers. Cancer Epidemiol Biomarkers Prev (2010) 1.55
Long-term intervention with heparins in a rat model of peritoneal dialysis. Perit Dial Int (2009) 1.54
Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy. J Hepatol (2010) 1.52
Colorectal cancer epigenetics: complex simplicity. J Clin Oncol (2011) 1.47
Genomic alterations in primary gastric adenocarcinomas correlate with clinicopathological characteristics and survival. Cell Oncol (2004) 1.46
Smoothing waves in array CGH tumor profiles. Bioinformatics (2009) 1.45
Risk of colorectal cancer in patients with Barrett's esophagus: A Dutch population-based study. Am J Gastroenterol (2009) 1.44
Breast cancer surgery-induced immunomodulation. J Surg Oncol (2010) 1.44
Macrophages direct tumour histology and clinical outcome in a colon cancer model. J Pathol (2005) 1.40
Genomic profiling of gastric cancer predicts lymph node status and survival. Oncogene (2003) 1.40
Endoscopic trimodal imaging versus standard video endoscopy for detection of early Barrett's neoplasia: a multicenter, randomized, crossover study in general practice. Gastrointest Endosc (2010) 1.27
Integrated genomic and transcriptional profiling identifies chromosomal loci with altered gene expression in cervical cancer. Genes Chromosomes Cancer (2008) 1.26
Retracted Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. Mult Scler Int (2011) 1.26
Across array comparative genomic hybridization: a strategy to reduce reference channel hybridizations. Genes Chromosomes Cancer (2008) 1.25
Test performance of immunologic fecal occult blood testing and sigmoidoscopy compared with primary colonoscopy screening for colorectal advanced adenomas. Cancer Prev Res (Phila) (2011) 1.23
Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes. Acta Neuropathol (2012) 1.22
Rapid quantification of myocardial fibrosis: a new macro-based automated analysis. Cell Oncol (Dordr) (2011) 1.22
Determination of amplicon boundaries at 20q13.2 in tissue samples of human gastric adenocarcinomas by high-resolution microarray comparative genomic hybridization. J Pathol (2003) 1.21
Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J Clin Invest (2014) 1.21
Protein expression of B-cell lymphoma gene 6 (BCL-6) in invasive breast cancer is associated with cyclin D1 and hypoxia-inducible factor-1alpha (HIF-1alpha). Oncogene (2003) 1.20
Does delay in diagnosing colorectal cancer in symptomatic patients affect tumor stage and survival? A population-based observational study. BMC Cancer (2010) 1.20
KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA. J Mol Diagn (2012) 1.19
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs (2015) 1.16
Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression. Tumour Biol (2010) 1.16
Subnuclear proteomics in colorectal cancer: identification of proteins enriched in the nuclear matrix fraction and regulation in adenoma to carcinoma progression. Mol Cell Proteomics (2010) 1.16
Dendritic cells recognize tumor-specific glycosylation of carcinoembryonic antigen on colorectal cancer cells through dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin. Cancer Res (2005) 1.16
BMP-7 blocks mesenchymal conversion of mesothelial cells and prevents peritoneal damage induced by dialysis fluid exposure. Nephrol Dial Transplant (2010) 1.15
The perioperative period is an underutilized window of therapeutic opportunity in patients with colorectal cancer. Ann Surg (2009) 1.15
TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression. Gut (2011) 1.15
Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan. Gastroenterology (2011) 1.15
The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma. Cancer Immunol Immunother (2006) 1.14
iTRAQ-based proteomics profiling reveals increased metabolic activity and cellular cross-talk in angiogenic compared with invasive glioblastoma phenotype. Mol Cell Proteomics (2009) 1.14
Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS One (2008) 1.14
Better preservation of the peritoneum in rats exposed to amino acid-based peritoneal dialysis fluid. Perit Dial Int (2005) 1.12
Focal aberrations indicate EYA2 and hsa-miR-375 as oncogene and tumor suppressor in cervical carcinogenesis. Genes Chromosomes Cancer (2012) 1.10
Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology. Cell Oncol (Dordr) (2014) 1.09
Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. J Immunol (2008) 1.08
A novel human IgA monoclonal antibody protects against tuberculosis. J Immunol (2011) 1.07
Promoter DNA methylation of oncostatin m receptor-beta as a novel diagnostic and therapeutic marker in colon cancer. PLoS One (2009) 1.06
Proteomic profiling of Mycobacterium tuberculosis identifies nutrient-starvation-responsive toxin-antitoxin systems. Mol Cell Proteomics (2013) 1.05
Biopsy strategies for endoscopic surveillance of pre-malignant gastric lesions. Helicobacter (2010) 1.05
High resolution analysis of DNA copy-number aberrations of chromosomes 8, 13, and 20 in gastric cancers. Virchows Arch (2009) 1.04
Proteomics of colorectal cancer: overview of discovery studies and identification of commonly identified cancer-associated proteins and candidate CRC serum markers. J Proteomics (2010) 1.04
Candidate driver genes in focal chromosomal aberrations of stage II colon cancer. J Pathol (2010) 1.03
Proteomics in colorectal cancer translational research: biomarker discovery for clinical applications. Clin Biochem (2012) 1.03
Promoter methylation precedes chromosomal alterations in colorectal cancer development. Cell Oncol (2006) 1.03
Promoter CpG island hypermethylation- and H3K9me3 and H3K27me3-mediated epigenetic silencing targets the deleted in colon cancer (DCC) gene in colorectal carcinogenesis without affecting neighboring genes on chromosomal region 18q21. Carcinogenesis (2009) 1.03
Colorectal adenoma to carcinoma progression is accompanied by changes in gene expression associated with ageing, chromosomal instability, and fatty acid metabolism. Cell Oncol (Dordr) (2012) 1.02
Interval cancers after colonoscopy-insights and recommendations. Nat Rev Gastroenterol Hepatol (2012) 1.02
Alternative cleavage and polyadenylation during colorectal cancer development. Clin Cancer Res (2012) 1.02
Molecular tests for colorectal cancer screening. Clin Colorectal Cancer (2011) 1.01
Factors contributing to peritoneal tissue remodeling in peritoneal dialysis. Perit Dial Int (2009) 1.01
Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. J Immunol (2005) 1.01
Differential glycosylation of MUC1 and CEACAM5 between normal mucosa and tumour tissue of colon cancer patients. Int J Cancer (2011) 1.01
A homozygous MSH6 mutation in a child with café-au-lait spots, oligodendroglioma and rectal cancer. Fam Cancer (2004) 1.00
Colonoscopic yield of colorectal neoplasia in daily clinical practice. World J Gastroenterol (2009) 1.00